156072-86-5

Usage

Uses

Used in Pharmaceutical Synthesis:
5-bromo-3-methylpicolinonitrile is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with improved therapeutic properties and efficacy.
Used in Organic Compounds Synthesis:
This chemical compound is employed as a building block in the production of a wide range of organic compounds. Its presence in these compounds contributes to their specific chemical and physical properties, making it an essential component in organic chemistry.
Used in Functional Materials Production:
5-bromo-3-methylpicolinonitrile is used as a precursor in the creation of functional materials with tailored properties. These materials can be applied in various industries, such as electronics, coatings, and adhesives, due to their unique characteristics.
Used in Agrochemicals Development:
5-bromo-3-methylpicolinonitrile is also utilized in the development of agrochemicals, which are essential for enhancing crop protection and improving agricultural productivity. Its incorporation into agrochemical formulations can lead to the creation of more effective and targeted pest control solutions.
Used in Drug Discovery:
5-bromo-3-methylpicolinonitrile plays a significant role in drug discovery, where it is employed as a reagent to explore new chemical entities with potential therapeutic applications. Its diverse reactivity allows researchers to investigate various chemical pathways and interactions, leading to the identification of novel drug candidates.

Upstream product

• 252056-70-5 5-amino-3-methylpyridine-2-carbonitrile 
• 3430-21-5 5-bromo-3-methyl-pyridin-2-ylamine 
• 3430-18-0 2,5-dibromo-3-methylpyridine 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 544-92-3 copper(I) cyanide 
• 65169-63-3 3-methyl-5-nitropyridine-2-carbonitrile 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 1375301-90-8 3-bromo-7H-[1,7]naphthyridin-8-one 
• 1600511-75-8 8-chloro-3-methoxy-1,7-naphthyridine 
• 1569695-13-1 C₉H₈N₂O₂ 
• 1256792-17-2 (5-methoxy-3-methylpyridin-2-yl)methanamine 
• 1150561-70-8 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-cyanopyridine 
• 1416000-33-3 3-methyl-5-(9-oxo-10-(3-(trifluoromethyl) phenyl)-9,10-dihydropyrido[3,2-c][1,5] naphthyridin-2-yl)-2-cyanopyridine 
• 1430058-63-1 2-{3-(3-fluorophenyl)-2-[3-(1-methyl-1H-pyrazol-5-yl)-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]propyl}-1H-isoindole-1,3(2H)-dione 
• 1430058-61-9 2-{3-(3-fluorophenyl)-2-[3-(1-methyl-1H-pyrazol-5-yl)-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]propyl}-1H-isoindole-1,3(2H)-dione 
• 1430057-34-3 6-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one 
• 1430057-33-2 6-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-3-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one 
• 1430058-59-5 2-[(2S)-2-[3-(4-chloro-1-methyl-1H-pyrazol-5-yl)-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430058-57-3 2-[(2S)-2-(3-bromo-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1048678-21-2 5-bromo-3-bromomethylpyridine-2-carboxylic acid methyl ester 
• 213771-32-5 5-bromo-3-methylpyridine-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of pyridone–aminal derivatives as MNK1/2 inhibitors

Excessive phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) plays a major role in the dysregulation of mRNA translation and the activation of tumor cell signaling. eIF4E is exclusively phosphorylated by mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) on Ser209. So, MNK1/2 inhibitors could decrease the level of p-eIF4E and regulate tumor-associated signaling pathways. A series of pyridone–aminal derivatives were synthesized and evaluated as MNK1/2 inhibitors. Several compounds exhibited great inhibitory activity against MNK1/2 and selected compounds showed moderate to excellent anti-proliferative potency against hematologic cancer cell lines. In particular, compound 42i (MNK1 IC50 = 7.0 nM; MNK2 IC50 = 6.1 nM) proved to be the most potent compound against TMD-8 cell line with IC50 value of 0.91 μM. Furthermore, 42i could block the phosphorylation level of eIF4E in CT-26 cell line, and 42i inhibited the tumor growth of CT-26 allograft model significantly. These results indicated that compound 42i was a promising MNK1/2 inhibitor for the potent treatment of colon cancer.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylax

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Synthesis and Properties of a Novel Pyridineoxazoline Containing Optically Active Helical Polymer as a Catalyst Ligand for Asymmetric Diels-Alder Reaction

A novel pyridineoxazoline (PyOx) containing helical polymer, poly{(-)-(S)-4-tert-butyl-2-[5-(4-tert-butylphenyl)-3-vinylpyridin-2-yl]-oxazoline} (PA), was designed and synthesized to approach the effect of chain conformation on the catalytic property. Its

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophyla

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylax

NOVEL COMPOUNDS

The preseent invention relates to novel retinoid-related orphan receptor gamma(RORγ)modulators and their use in the treatment ofdiseases mediated by RORγ.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS

The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.